Pfizer Investigational Site
Singapore, 188770
NCT Number: NCT00894660
The study will determine if amodiaquine tablet (Pfizer), an antimalaria agent, is pharmaceutically equivalent to a comparator product (Arsuamoon-Guilin China).
Looking for future studies?
Notify Me21 year–55 year
All sexes
Interventional
Phase 1
Singapore, 188770
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Oral tablet, single dose, 1 X 300 MG
Other names: Camoquin
Oral tablet, single dose, 2 X 150 MG
Other names: Camoquin
Time frame: 1 month
Time frame: 1 month
Pfizer
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06992297
Falciparum Malaria, Infections
Marseille, France
View Trial DetailsNCT03916003
Falciparum Malaria, Infections
Upazila, Bangladesh
View Trial DetailsNCT04422015
Falciparum Malaria, Infections
Manhiça, Mozambique
View Trial DetailsNCT04222088
Falciparum Malaria, Infections
View Trial Details